Literature DB >> 25213440

Murmur intensity in small-breed dogs with myxomatous mitral valve disease reflects disease severity.

I Ljungvall1, M Rishniw, F Porciello, L Ferasin, D G Ohad.   

Abstract

OBJECTIVES: To determine whether murmur intensity in small-breed dogs with myxomatous mitral valve disease reflects clinical and echocardiographic disease severity.
METHODS: Retrospective multi-investigator study. Records of adult dogs Ä20 kg with myxomatous mitral valve disease were examined. Murmur intensity and location were recorded and compared with echocardiographic variables and functional disease status. Murmur intensities in consecutive categories were compared for prevalences of congestive heart failure, pulmonary hypertension and cardiac remodelling.
RESULTS: 578 dogs [107 with "soft" (30 Grade I/VI and 77 II/VI), 161 with "moderate" (Grade III/VI), 160 with "loud" (Grade IV/VI) and 150 with "thrilling" (Grade V/VI or VI/VI) murmurs] were studied. No dogs with soft murmurs had congestive heart failure, and 90% had no remodelling. However, 56% of dogs with "moderate", 29% of dogs with "loud" and 8% of dogs with "thrilling" murmurs and subclinical myxomatous mitral valve disease also had no remodelling. Probability of a dog having congestive heart failure or pulmonary hypertension increased with increasing murmur intensity. CLINICAL SIGNIFICANCE: A 4-level murmur grading scheme separated clinically meaningful outcomes in small-breed dogs with myxomatous mitral valve disease. Soft murmurs in small-breed dogs are strongly indicative of subclinical heart disease. Thrilling murmurs are associated with more severe disease. Other murmurs are less informative on an individual basis.
© 2014 British Small Animal Veterinary Association.

Entities:  

Mesh:

Year:  2014        PMID: 25213440     DOI: 10.1111/jsap.12265

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  7 in total

1.  Preliminary Investigation of Cardiovascular-Renal Disorders in Dogs with Chronic Mitral Valve Disease.

Authors:  E Martinelli; C Locatelli; S Bassis; S Crosara; S Paltrinieri; P Scarpa; I Spalla; A M Zanaboni; C Quintavalla; P Brambilla
Journal:  J Vet Intern Med       Date:  2016-09       Impact factor: 3.333

2.  Degenerative Valvular Disease in the Cavalier King Charles Spaniel: Results of the UK Breed Scheme 1991-2010.

Authors:  S Swift; A Baldin; P Cripps
Journal:  J Vet Intern Med       Date:  2017-01-05       Impact factor: 3.333

3.  Prevalence of Arrhythmias in Dogs Examined between 2008 and 2014.

Authors:  Agnieszka Noszczyk-Nowak; Marcin Michałek; Ewelina Kałuża; Alicja Cepiel; Urszula Pasławska
Journal:  J Vet Res       Date:  2017-04-04       Impact factor: 1.744

4.  Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom.

Authors:  Madeleine J Mattin; David C Brodbelt; David B Church; Adrian Boswood
Journal:  J Vet Intern Med       Date:  2018-12-18       Impact factor: 3.333

5.  Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease.

Authors:  Jenny Wilshaw; Steven L Rosenthal; Gerhard Wess; Dave Dickson; Luca Bevilacqua; Emily Dutton; Michael Deinert; Ricardo Abrantes; Ingo Schneider; Mark A Oyama; Sonya G Gordon; Jonathan Elliott; Dong Xia; Adrian Boswood
Journal:  J Vet Intern Med       Date:  2021-03-01       Impact factor: 3.333

6.  Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom.

Authors:  M J Mattin; A Boswood; D B Church; D C Brodbelt
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

7.  Association between Cardiac Auscultation and Echocardiographic Findings in Warmblood Horses.

Authors:  Jakob Hövener; Julie Pokar; Roswitha Merle; Heidrun Gehlen
Journal:  Animals (Basel)       Date:  2021-12-05       Impact factor: 2.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.